Cmax fell by about 21% in one crossover study, though 24-hour AUC was unchanged [1]
If widely adopted, oral GLP-1 therapies could reshape obesity treatment, making effective medications easier to use, distribute, and integrate into long-term care
The study highlights that those experiencing fewer side effects are less likely to quit, emphasizing the impact of tolerability and affordability on long-term use
A 5mg/mL concentration works perfectly for weeks 1-12 but becomes impractical at 8mg (you would need 160 units, exceeding a standard syringe)
GLP-1 plays a pivotal role in regulating blood sugar levels and appetite, making it an effective tool for sustainable weight management
A new, higher dose of Wegovy, which FDA officials recently approved, may help people lose more weight with semaglutide